Beyond Branch Patency: Timing, Bleeding Phenotype, and Organ Risk in Antithrombotic Therapy After Branched EVAR

Cardiovascular Drugs and Therapy · Published 2026-06-10 · DOI 10.1007/s10557-026-07899-y

Authors (1)

Jiaqian Ying

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Ying, J. (2026). Beyond Branch Patency: Timing, Bleeding Phenotype, and Organ Risk in Antithrombotic Therapy After Branched EVAR. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-026-07899-y

Related articles

• Circulating Circ_0089762 Predicts Adverse Outcomes in Acute Myocardial Infarction Via Regulating miR‑938/STAT3‑Mediated Endothelial Dysfunction · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Guideline-directed Low-density Lipoprotein Cholesterol Management After Acute Coronary Syndrome in Patients With Mental Illness: a Population-based Study · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Reflections on Oral Beta Blocker Therapy and Long-term Outcomes after Myocardial Infarction in Preserved Left Ventricular Function · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Sennoside A Ameliorates Myocardial Fibrosis After Myocardial Infarction by Binding to KDM4B and Regulates IRX2 Expression · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Cellular Senescence in Diabetic Cardiomyopathy: Mechanistic Insights and Therapeutic Perspectives · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Hyperuricemia and Hypoxic Pulmonary Hypertension: Pathogenic Links, Clinical Evidence, and Emerging Therapeutic Insights · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Aspirin Instead of Clopidogrel after Percutaneous Coronary Intervention in Atrial Fibrillation: More than just an Option · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Comparing the 2025 ESC/EAS Focused Update and the 2026 ACC/AHA Dyslipidemia Guideline: Convergences, Divergences, and Practical Implications · Cardiovascular Drugs and Therapy · 2026 · Same journal
• Complement Component C4B Prioritization Through Drug‒Target Mendelian Randomization and Proteomic Analysis Reveals a Novel Therapeutic Target for Calcific Aortic Valve Stenosis · Cardiovascular Drugs and Therapy · 2026 · Same journal